Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jul 5;78(7):1658-1666.
doi: 10.1093/jac/dkad147.

Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial

Jesús Sojo-Dorado  1   2 , Inmaculada López-Hernández  1   2 , Alicia Hernández-Torres  3 , Pilar Retamar-Gentil  1   2 , Esperanza Merino de Lucas  4   5 , Laura Escolà-Vergé  2   6 , Elena Bereciartua  7 , Elisa García-Vázquez  3 , Vicente Pintado  2   8 , Lucía Boix-Palop  9 , Clara Natera-Kindelán  2   10 , Luisa Sorlí  11 , Nuria Borrell  12 , Concha Amador-Prous  13 , Evelyn Shaw  2   14 , Alfredo Jover-Saenz  15 , Jose Molina  2   16 , Rosa M Martínez-Álvarez  17 , Carlos J Dueñas  18 , Jorge Calvo-Montes  2   19 , María Lecuona  20 , Virginia Pomar  21 , Irene Borreguero  22 , Virginia Palomo-Jiménez  1 , Fernando Docobo-Pérez  1 , Álvaro Pascual  1   2 , Jesús Rodríguez-Baño  1   2
Affiliations
Randomized Controlled Trial

Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial

Jesús Sojo-Dorado et al. J Antimicrob Chemother. .

Abstract

Background: Fosfomycin is a potentially attractive option as step-down therapy for bacteraemic urinary tract infections (BUTI), but available data are scarce. Our objective was to compare the effectiveness and safety of fosfomycin trometamol and other oral drugs as step-down therapy in patients with BUTI due to MDR Escherichia coli (MDR-Ec).

Methods: Participants in the FOREST trial (comparing IV fosfomycin with ceftriaxone or meropenem for BUTI caused by MDR-Ec in 22 Spanish hospitals from June 2014 to December 2018) who were stepped-down to oral fosfomycin (3 g q48h) or other drugs were included. The primary endpoint was clinical and microbiological cure (CMC) 5-7 days after finalization of treatment. A multivariate analysis was performed using logistic regression to estimate the association of oral step-down with fosfomycin with CMC adjusted for confounders.

Results: Overall, 61 patients switched to oral fosfomycin trometamol and 47 to other drugs (cefuroxime axetil, 28; amoxicillin/clavulanic acid and trimethoprim/sulfamethoxazole, 7 each; ciprofloxacin, 5) were included. CMC was reached by 48/61 patients (78.7%) treated with fosfomycin trometamol and 38/47 (80.9%) with other drugs (difference, -2.2; 95% CI: -17.5 to 13.1; P = 0.38). Subgroup analyses provided similar results. Relapses occurred in 9/61 (15.0%) and 2/47 (4.3%) of patients, respectively (P = 0.03). The adjusted OR for CMC was 1.11 (95% CI: 0.42-3.29, P = 0.75). No relevant differences in adverse events were seen.

Conclusions: Fosfomycin trometamol might be a reasonable option as step-down therapy in patients with BUTI due to MDR-Ec but the higher rate of relapses would need further assessment.

PubMed Disclaimer

References

    1. Al-Hasan MN, Eckel-Passow JE, Baddour LM. Bacteremia complicating gram-negative urinary tract infections: a population-based study. J Infect 2010; 60: 278–85. 10.1016/j.jinf.2010.01.007 - DOI - PMC - PubMed
    1. Rodríguez-Baño J, López-Prieto MD, Portillo MM et al. Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals. Clin Microbiol Infect 2010; 16: 1408–13. 10.1111/j.1469-0691.2010.03089.x - DOI - PubMed
    1. Tamma PD, Conley AT, Cosgrove SE et al. Association of 30-day mortality with oral step-down vs continued intravenous therapy in patients hospitalized with Enterobacteriaceae bacteremia. JAMA Intern Med 2019; 179: 316–23. Erratum in: JAMA Intern Med 2019; 179:1607. 10.1001/jamainternmed.2018.6226 - DOI - PMC - PubMed
    1. Sutton JD, Stevens VW, Chang NN et al. Oral β-lactam antibiotics vs fluoroquinolones or trimethoprim-sulfamethoxazole for definitive treatment of Enterobacterales bacteremia from a urine source. JAMA Netw Open 2020; 3: e2020166. 10.1001/jamanetworkopen.2020.20166 - DOI - PMC - PubMed
    1. Saad S, Mina N, Lee C et al. Oral beta-lactam step down in bacteremic E. coli urinary tract infections. BMC Infect Dis 2020; 20: 785. 10.1186/s12879-020-05498-2 - DOI - PMC - PubMed

Publication types

MeSH terms